STA Pharmaceutical Co., Ltd., a WuXi AppTec subsidiary, has signed a supply agreement with the oncology-focused biopharmaceutical company, TESARO, Inc. for certain starting and intermediate materials for ZEJULA (Niraparib).   Under the five-year agreement, STA will provide certain starting and intermediate materials for the recently launched ZEJULA – an orally active and potent poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of ovarian cancer. ZEJULA was FDA-approved for epit...